Latest
Sources
Trade Ideas
Speakers
Sign in
Go
Lilly's Retevmo (selpercatinib) delivers substantial event-free survival benefit as an adjuvant therapy in early-stage RET fusion-positive lung cancer
Original source ↗
| February 16, 2026 at 11:45 UTC |
Finnhub - LLY
No analysis available.
Trade Ideas
Ticker
Direction
Speaker
Thesis
Time
LLY
NONE
Finnhub News
—
—